News | March 10, 2015

Radiotherapeutics the Driving Force of Nuclear Medicine, Report Says

Transition from SPECT to PET, growth of oncology imaging expected to push market over next five years

radiotherapeutics, nuclear medicine, PET, SPECT, MEDraysintell

March 10, 2015 — The first annual financial results of Xofigo (radium-223 dichloride) from Bayer are in line with the MEDraysintell analysis showing that the growth of nuclear medicine in the future will come through therapeutic radiopharmaceuticals (radiotherapeutics). Revenue for Xofigo – a product used in the treatment of prostate and bone cancers – reached EUR 157 million (US$ 209 million) in 2014.

There is a persistent common belief that a key driver for future growth in the nuclear medicine market will come from positron emission tomography (PET), with, for instance, the major switch in cardiology from single photon emission computed tomography (SPECT) to PET. Recent published analyst reports continue to predict a bright future for cardiology in PET, forgetting that the leading molecule has been on hold since 2013 and that other companies involved in this domain struggle to find the financial means to complete phase III trials.

MEDraysintell suggests in its report, “Opportunities in Nuclear Medicine,” a different evolution for the nuclear medicine market, with the main driver coming from radiotherapeutics, while diagnostic radiopharmaceuticals will maintain an average limited growth. In cardiology, SPECT will continue to progress on the basis of 99mTc (despite the 99Mo shortage issue that will be solved within the next 5 years) and in PET there is only a real future for the 82Sr/82Rb generator. A real interest in PET in cardiology will arise from applications in cardiovascular diseases (atherosclerosis, vulnerable plaque). PET in neurology has proven to be of high interest, but the healthcare system cannot absorb additional costs at this stage, or at least not before associated therapies for neurodegenerative diseases are available. Oncology will remain the primary area of interest for PET imaging with the introduction of more than half a dozen new tracers on the market within the next 5 years.

For more information: www.medraysintell.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...